Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: CVS stock price vs NWL: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at NWL's multiple
Needs NWL P/E.
Implied fair value · at CVS's multiple
Needs Annual EPS is negative, CVS P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
16 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
CVS HEALTH Corp · implied price per share
Bear
$43.35
Base
$58.49
Bull
$78.21
NEWELL BRANDS INC · implied price per share
Bear
-$9.19
Base
-$9.00
Bull
-$8.67
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Walgreens Boots Alliance, Inc.
CVS vs WBA
UNITEDHEALTH GROUP INC
CVS vs UNH
Walmart Inc.
CVS vs WMT
Cigna Group
CVS vs CI
HUMANA INC
CVS vs HUM
Elevance Health, Inc.
CVS vs ELV
PROCTER & GAMBLE Co
CVS vs PG
COLGATE PALMOLIVE CO
CVS vs CL
INTERNATIONAL BUSINESS MACHINES CORP
CVS vs IBM
CLOROX CO /DE/
CVS vs CLX
WHIRLPOOL CORP /DE/
CVS vs WHR
ESTEE LAUDER COMPANIES INC
CVS vs EL
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe CVS can sustain its 7.8% revenue growth and hold leverage near 4.4x net debt/EBITDA, then a hold-to-modestly-positive stance is appropriate because the stock already trades essentially at its P/S-implied value and is not obviously mispriced versus NWL.
CVS’s current price of $104.43 is almost exactly in line with the P/S implied price of $104.63, suggesting no meaningful valuation gap on this basis. Relative to NWL-implied range, CVS sits near the top end and just above the upper bound, which makes the setup look fairly priced rather than clearly discounted.
Supporting Metrics
